Chronic kidney disease (CKD) is currently ranked the ninth leading cause of death globally[1]. However, up to half of the cases may remain undetected despite the availability of… read more.
MannKind Corporation announced that the FDA has approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure (HF) or chronic kidney… read more.
Novartis announced that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of… read more.
Nearly half of Americans with kidney failure who are referred for transplantation never begin the process required to be considered for a new organ, a new study shows,… read more.
Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia (atrasentan) versus placebo in adults with IgA nephropathy (IgAN). Results were published in The… read more.
BD (Becton, Dickinson and Company) announced the introduction of the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD’s kidney stone care portfolio… read more.
Researchers report that weight-loss surgery improves outcomes for patients with obesity and chronic kidney disease by significantly reducing the risk of kidney failure, major cardiovascular events and death…. read more.
Speaking today at the 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) Jagbir Gill, MD, Associate Professor of Medicine in the Division… read more.
Kidney stones can cause some of the most intense pain people ever experience, affecting daily life and leading many to hospital emergency visits. It affects 1 in 11… read more.
People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and… read more.
Hansa Biopharma AB announced that the FDA has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User… read more.
The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
